REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
REGENERX BIOPHARMACEUTICALS, INC. (Amex: RGN) reported on several clinical studies with Thymosin beta 4 (Tb4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.
More from Release
More from Release
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment
- Sucampo (SCMP) Says AMITIZA Had Statistically Significant Results Following Two Phase 3s
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
